MindWalk™

Q4 & 2026 Fiscal Year End

Earnings Presentation

FY 2026

Presented by
Dr. Jennifer Bath, CEO

Date: 07.22.26

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of MindWalk Holdings Corp. (the "Company") securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company's securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company's potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company's long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "targeting" and "intend" and statements that an event or result "may", "will", "should", "could", or "might" occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company's management about the Company's business, planned acquisitions, future plans, anticipated events & other future conditions. All forward–looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company's business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company's most recent Annual Information Form, which is available under the Company's profile on EDGAR at www.sec.gov.edgar and SEDAR+ at www.sedarplus.ca for additional related risks factors that could materially affect the Company's operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

MindWalk™

Intro

A defining year: Our discovery engine and Bio-Native AI infrastructure came together as one integrated platform.

↗ Scientific Platform

↗ Technology Platform

↗ Commercial Traction

MindWalk™

Key highlights

Strategically built to shape change and strengthen growth potential

Data
ReefIQ™

AI
LensAI™

Lab
Antibody Discovery

The Vault
MindWalk Biologic Assets

Patented HYFT® Technology

Grew revenue 46%
Expanded gross margin to 59%

Signed first two recurring platform agreements

Launched ReefIQ™

Divestiture of non-core business complete

Regained Nasdaq compliance organically

Earned inclusion in the:
Russell 3000E index
Russell Microcap Index

20+ client-owned molecules advanced into the clinic

First client-owned discovery molecule with FDA approval

MindWalk™

A Bio-Native AI ecosystem built to expand drug discovery opportunity



LensAI™

Reasoning layer

ReefIQ™

Biological context layer

HYFT® Technology

Foundation layer

Patented technology
660 million biological patterns
25+ billion biological relationships

Launched ReefIQ Spring 2026

MindWalk

Scientific Platform

Discovery track record

20+ client-owned molecules to clinic

10 molecules currently in active Phase 1 - Phase 3 trials

4 molecules are first-in-class

Backed by **400 peer-reviewed publications and patents**

MindWalk™

Scientific Platform

Client-owned asset validation

FDA approval of client-owned asset

+ **Commercially launched** therapeutic antibody
+ Treating a rare autoimmune condition

MindWalk™

Scientific Platform

MindWalk assets and platform validation

Dengue Data

+ HYFT technology identified a pan-serotype conserved epitope
+ Validated *in vivo* across 2 independent campaigns

GLP-1

+ Designed receptor-agonist sequences *in silico*
+ *In vitro* testing showed GLP-1 receptor activation at or above semaglutide levels

Influenza

+ Identified a relational invariant across 2,000+ strains

Pandemic Response Platform

+ Ebola
+ Hantavirus

MindWalk™

Scientific Platform

ReefIQ

Filed IP Patent Protection

This is a structural filing, extending our foundational HYFT patent to the way biological context itself is organized inside our system.

MindWalk™

FY26 highlights

Financial market updates

Regained Nasdaq compliance organically

MindWalk was added to the Russell 3000E Index and the Russell Microcap Index

MindWalk

FY26 highlights

Rebranding and market visibility

Completed September 2025



MindWalk

FY26 highlights

Executive team additions

Chief Financial Officer
Scott Areglado

- Leads financial strategy and capital markets execution
- Background: scaling high-growth technology companies
- Enhancing capital access and supporting strategic growth initiatives

Chief Business Officer
Dr. Thomas Lynch

- Leads global platform expansion
- Decades of experience in enterprise commercialization
- Strengthening partner ecosystem and customer footprint

FY26 highlights

European divestiture

Strengthened balance sheet to focus on core business

+ Completed the sale of our Netherlands operations to AVS Bio

FY26 highlights

AMD collaboration

- + Featured partner at AMD Advancing AI 2026
- + AMD published a case study on our work together- highlighting measurable impact
- + Co-speakers at JonesTrading AI Day

Financial Update

Q4 & 2026 Fiscal Year End
Earnings Presentation

FY 2026

MindWalk

Revenue by period

(All values in CAD, in thousands)



~+46% growth YOY

MindWalk

Continued YoY Revenue Growth



MindWalk™

Cash balances



Thanks

Contact: info@mindwalk.com

MindWalkai.com

MindWalk™

Questions

Q4 & 2026 Fiscal Year End
Earnings Presentation

FY 2026